Although TP53-mutant cancers generate neoantigens, TP53-mutated MDS/AML typically have lower tumor mutational burdens, suggesting immune evasion mechanisms hinder anti-tumor responses (37). The gene discussed is TP53; the disease is myelodysplastic syndrome.